ArticleJournal of the Association for Research in Otolaryngology : JARO2020
Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents.
Article in Journal of the Association for Research in Otolaryngology : JARO, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 45 citations in OpenAlex.
- MCU knockdown attenuates cisplatin-induced damage of auditory cells: potential involvement of PI3K/AKT/mTOR signaling and autophagy-related processes.Frontiers in pharmacology · 2026Article
- Octahedral [(8-quinolinyl/phenanthridinyl)amine)Ga(III)] complexes, reactivity, affinity for biomolecules, anti-cancer and computational evaluations.Reaction kinetics, mechanisms and catalysis · 2026Article
- Anti-CD24 antibody-nitric oxide donor conjugates bearing a self-bioorthogonal cleavable linker.Acta pharmaceutica Sinica. B · 2025Article
- CORM‑2 reduces cisplatin accumulation in the mouse inner ear and protects against cisplatin-induced ototoxicity.Journal of advanced research · 2024Article
- The Therapeutic Mechanisms of Honey in Mitigating Toxicity from Anticancer Chemotherapy Toxicity: A Review.Journal of xenobiotics · 2024Review
- KSR1 Knockout Mouse Model Demonstrates MAPK Pathway's Key Role in Cisplatin- and Noise-induced Hearing Loss.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024Article
- Large-scale annotated dataset for cochlear hair cell detection and classification.Scientific data · 2024Article
- Hearing loss during chemotherapy: prevalence, mechanisms, and protection.American journal of cancer research · 2024Review
- Molecular Characteristics of Cisplatin-Induced Ototoxicity and Therapeutic Interventions.International journal of molecular sciences · 2023Review
- KSR1 knockout mouse model demonstrates MAPK pathway's key role in cisplatin- and noise-induced hearing loss.bioRxiv : the preprint server for biology · 2023Article
- Large-scale annotated dataset for cochlear hair cell detection and classification.bioRxiv : the preprint server for biology · 2023Article
- The ototoxic drug cisplatin localises to stress granules altering their dynamics and composition.Journal of cell science · 2023Article
- The hair cell analysis toolbox is a precise and fully automated pipeline for whole cochlea hair cell quantification.PLoS biology · 2023Article
- Emerging and established therapies for chemotherapy-induced ototoxicity.Journal of cancer survivorship : research and practice · 2023Review
- Special considerations in the design and implementation of pediatric otoprotection trials.Journal of cancer survivorship : research and practice · 2023Review
- Hearing Function, Degeneration, and Disease: Spotlight on the Stria Vascularis.Frontiers in cell and developmental biology · 2022Review
- Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data.Frontiers in oncology · 2022Article
- Multiplex immunohistochemistry reveals cochlear macrophage heterogeneity and local auditory nerve inflammation in cisplatin-induced hearing loss.Frontiers in neurology · 2022Article
- Cisplatin Mouse Models: Treatment, Toxicity and Translatability.Biomedicines · 2021Review
- Experimental animal models of drug-induced sensorineural hearing loss: a narrative review.Annals of translational medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Cisplatin is a widely used anti-cancer drug used to treat a variety of cancer types. One of the side effects of this life-saving drug is irreversible ototoxicity, resulting in permanent hearing loss in many patients. In order to understand why cisplatin is particularly toxic to the inner ear, we compared the hearing loss and cochlear uptake of cisplatin to that of two related drugs, carboplatin and oxaliplatin. These three drugs are similar in that each contains a core platinum atom; however, carboplatin and oxaliplatin are considered less ototoxic than cisplatin. We delivered these three drugs to mice using a 6-week cyclic drug administration protocol. We performed the experiment twice, once using equimolar concentrations of the drugs and once using concentrations of the drugs more proportional to those used in the clinic. For both concentrations, we detected a significant hearing loss caused by cisplatin and no hearing loss caused by carboplatin or oxaliplatin. Cochlear uptake of each drug was measured using inductively coupled plasma mass spectrometry (ICP-MS) to detect platinum. Cochlear platinum levels were highest in mice treated with cisplatin followed by oxaliplatin, while carboplatin was largely excluded from the cochlea. Even when the drug doses were increased, cochlear platinum remained low in mice treated with oxaliplatin or carboplatin. We also examined drug clearance from the inner ear by measuring platinum levels at 1 h and 24 h after drug administration. Our findings suggest that the reduced cochlear platinum we observed with oxaliplatin and carboplatin were not due to increased clearance of these drugs relative to cisplatin. Taken together, our data indicate that the differential ototoxicity among cisplatin, carboplatin, and oxaliplatin is attributable to differences in cochlear uptake of these three drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.